From COVID-19 Vaccines and Soft Tissue Filler Reactions to Biologic Therapy for Psoriasis
The April issue of the Journal of Drugs in Dermatology features the perfect mix of medical, aesthetic, and surgical dermatology articles on topics ranging from COVID-19 Vaccines and Soft Tissue Filler Reactions to Biologic Therapy for Psoriasis. Straight from the JDD Editor’s desk, we share this month’s issue highlights:
A survey was designed to capture the incidence of adverse events in G …
The April issue of the Journal of Drugs in Dermatology features the perfect mix of medical, aesthetic, and surgical dermatology articles on topics ranging from COVID-19 Vaccines and Soft Tissue Filler Reactions to Biologic Therapy for Psoriasis. Straight from the JDD Editor’s desk, we share this month’s issue highlights:
A survey was designed to capture the incidence of adverse events in G … 
ABSTRACT
The risk of post-inflammatory hyperpigmentation (PIH) in patients undergoing dermatologic procedures is well known. It is especially common after laser procedures and chemical peels but can be seen with any procedure. PIH is also a sequela of acne, burns, and other trauma. High-risk patients are thought to have excessive production and abnormal distribution of melanin within the skin tha … 
Dermatophyte infections are estimated to affect about 25% of the world’s population, representing some of the most common infections in the world. Conditions such as onychomycosis and tinea capitis may significantly impact quality of life by way of their symptoms or appearance, making adequate treatment important. Oral and topical formulations of terbinafine are commonly used on- and off-label f … 
Straight from the desk of ODAC Medical Director, Dr. Adam Friedman, we share what’s popping in acne (spoiler alert: quite a lot!). According to Dr. Friedman, the innovation drought is over! Watch as he reviews all new topical and oral therapeutics (some of which are completely new active agents) and while at it, shares and debunks important information related to the management of acne vulgaris … 
Treatment of malignancy with anti-programmed cell death 1 (PD-1) immune checkpoint inhibitors can cause mucocutaneous side effects resulting from T cell activation. Due to their recent development, the full side effect profile remains to be fully elucidated, however dermatologic adverse events are most common. The main oral toxicities of these immune checkpoint inhibitors include: xerostomia, dysg … 